These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 580398)

  • 1. Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man.
    Schwartz DE; Brandt R
    Arzneimittelforschung; 1978; 28(2):302-7. PubMed ID: 580398
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat.
    Schwartz DE; Jordan JC; Ziegler WH
    Eur J Clin Pharmacol; 1974; 7(1):39-45. PubMed ID: 4853605
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor.
    Doller HJ; Connor JD; Lock DR; Sloviter RS; Dvorchik BH; Vesell ES
    Drug Metab Dispos; 1978; 6(2):164-8. PubMed ID: 26532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
    Hagan RM; Raxworthy MJ; Gulliver PA
    Biochem Pharmacol; 1980 Dec; 29(23):3123-6. PubMed ID: 7447951
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on pharmacokinetics and biotransformation of oxepinac in mouse, rat, dog and man.
    Hakusui H; Suzuki W; Takegoshi T; Saito T; Sano M
    Arzneimittelforschung; 1978; 28(3):456-61. PubMed ID: 580756
    [No Abstract]   [Full Text] [Related]  

  • 6. Absorption and tissue distribution of flunarizine in rats, pigs and dogs.
    Michiels M; Hendriks R; Knaeps F; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1983; 33(8):1135-42. PubMed ID: 6685490
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood-brain barrier to carbidopa (MK-486) and Ro 4-4602, peripheral dopa decarboxylase inhibitors.
    Clark WG; Oldendorf WH; Dewherst WG
    J Pharm Pharmacol; 1973 May; 25(5):416-8. PubMed ID: 4146401
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man.
    Vickers S; Stuart EK; Bianchine JR; Hucker HB; Jaffe ME; Rhodes RE; Vandenheuvel WJ
    Drug Metab Dispos; 1974; 2(1):9-22. PubMed ID: 4150141
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacokinetics of hydrazine sulfate in intact and tumor-bearing rats].
    Filov VA; Popov BV; Bezel' VS
    Farmakol Toksikol; 1982; 45(4):78-81. PubMed ID: 7128794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of zopiclone.
    Gaillot J; Heusse D; Hougton GW; Marc Aurele J; Dreyfus JF
    Int Pharmacopsychiatry; 1982; 17 Suppl 2():76-91. PubMed ID: 7188377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic aspect of tritium-labeled glycosaminoglycans (mesoglycan). Their absorption in rat and monkey and tissue distribution in rat.
    Zanolo G; Giachetti C; Mascellani G; Magliocca R; Ferrari G
    Boll Chim Farm; 1984 May; 123(5):223-35. PubMed ID: 6487425
    [No Abstract]   [Full Text] [Related]  

  • 12. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in Rats, Dogs and Monkeys and of AD-810 in Men.
    Matsumoto K; Miyazaki H; Fujii T; Kagemoto A; Maeda T; Hashimoto M
    Arzneimittelforschung; 1983; 33(7):961-8. PubMed ID: 6138046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog.
    Naito K; Furuuchi S; Yamada Y; Otsuka M; Harigaya S
    Arzneimittelforschung; 1986 Apr; 36(4):643-51. PubMed ID: 3718588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of Morocromen in animals and man (author's transl)].
    Dell HD; Jacobi H; Kamp R; Lorenz D
    Arzneimittelforschung; 1982; 32(5):492-8. PubMed ID: 7201825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.